This is a preview of subscription content, access via your institution
Access options
Subscribe to Journal
Get full journal access for 1 year
$119.00
only $9.92 per issue
All prices are NET prices.
VAT will be added later in the checkout.
Tax calculation will be finalised during checkout.
Buy article
Get time limited or full article access on ReadCube.
$32.00
All prices are NET prices.


References
Biggs JC, Szer J, Crilley P et al. Treatment of chronic myeloid leukaemia with allogeneic bone marrow transplantation after preparation with BuCy2. Blood 1992; 80: 1352–1357.
Weisdorf D, Haake R, Blazar B et al. Treatment of moderate/severe acute GvHD after allogeneic bone marrow transplantation: an analysis of clinical risk features and outcome. Blood 1990; 75: 1024–1030.
Martin PJ, Schoch G, Fisher L et al. A retrospective analysis of therapy for acute graft versus host disease: secondary treatment. Blood 1991; 77: 1821–1828.
Remberger M, Aschan J, Barkholt L et al. Treatment of acute graft-versus-host disease with antithymocyte globulin. Clin Transplant 2001; 15: 147–153.
Abhyankar S, Godder K, Christiansen N et al. Treatment of resistant acute and chronic graft-versus-host disease with mycophenolate mofetil. Blood 1998; 92 (Suppl.): 340b (abstract 4467).
Farag SS, Bruner R . Monoclonal antibodies for the prevention and treatment of graft-versus-host disease. Semin Oncol 2003; 30: 509–519.
Mufti GJ, Fishlock K, Arno M et al. Peripheral blood dendritic cells express CD52 and are depleted in-vivo by treatment with Campath-1H. Blood 2001; 98: 2048 (abstract 1543).
Naparstek E, Or R, Nagler A et al. T-cell depleted allogeneic bone marrow transplantation for acute leukaemia using Campath-1 antibodies and post transplant administration of donor's peripheral blood lymphocytes for prevention of relapse. Br J Haematol 1995; 89: 506–515.
Varadi G, Reuven OR, Slavin S et al. In vivo Campath-1 monoclonal antibodies: a novel mode of therapy for acute graft-versus-host disease. Am J Haematol 1996; 52: 236–237.
Carella AM, Beltrami G, Scalzulli PR et al. Alemtuzumab can successfully treat steroid-refractory acute graft-versus-host disease (aGvHD). BMT 2004; 33: 131–132.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Wandroo, F., Auguston, B., Cook, M. et al. Successful use of Campath-1H in the treatment of steroid refractory liver GvHD. Bone Marrow Transplant 34, 285–287 (2004). https://doi.org/10.1038/sj.bmt.1704573
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.bmt.1704573
This article is cited by
-
Alemtuzumab as salvage therapy for steroid and ATG/etanercept-refractory acute GVHD
Bone Marrow Transplantation (2011)
-
Therapy of steroid-refractory acute GVHD with CD52 antibody alemtuzumab is effective
Bone Marrow Transplantation (2011)
-
Severe autologous GVHD after hematopoietic progenitor cell transplantation for multiple myeloma
Bone Marrow Transplantation (2009)